During the past decade, Chu Reims conducted 388 clinical trials. In the 10-year time frame, 388 clinical trials started and 56 clinical trials were completed, i.e. on average, 14.4% percent of trials that started reached the finish line to date. In the past 5 years, 162 clinical trials started and 30 clinical trials were completed. i.e. 18.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chu Reims" #1 sponsor was "CHU de Reims" with 138 trials, followed by "The Lymphoma Academic Research Organisation" with 20 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 19 trials sponsored, "Pfizer" with 16 trials sponsored and "UNICANCER" with 16 trials sponsored. Other sponsors include 426 different institutions and companies that sponsored additional 147 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chu Reims" #1 collaborator was "Ministry of Health, France" with 13 trials as a collaborator, "Roche Pharma AG" with 10 trials as a collaborator, "National Cancer Institute, France" with 8 trials as a collaborator, "Institut National de la Santé Et de la Recherche Médicale, France" with 7 trials as a collaborator and "Amgen" with 6 trials as a collaborator. Other collaborators include 360 different institutions and companies that were collaborators in the rest 263 trials.

According to Clinical.Site data, the most researched conditions in "Chu Reims" are "Multiple Myeloma" (13 trials), "Colorectal Cancer" (11 trials), "Alzheimer Disease" (9 trials), "Metastatic Colorectal Cancer" (9 trials) and "Ulcerative Colitis" (9 trials). Many other conditions were trialed in "Chu Reims" in a lesser frequency.

Most popular intervention types in "Chu Reims" are "Drug" (303 trials), "Other" (160 trials), "Procedure" (60 trials), "Device" (53 trials) and "Biological" (40 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (48 trials), "Rituximab" (12 trials), "fluorouracil" (9 trials), "Cyclophosphamide" (8 trials) and "Lenalidomide" (8 trials). Other intervention names were less common.

The vast majority of trials in "Chu Reims" are 617 trials for "All" genders, 20 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 183 active trials in "Chu Reims". 10 are not yet recruiting, 123 are recruiting, 48 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 318 completed trials in Chu Reims, 1 suspended trials, and 53 terminated clinical trials to date.

Out of the total trials that were conducted in Chu Reims, 4 "Phase 1" clinical trials were conducted, 122 "Phase 2" clinical trials and 169 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 31 trials, and there were also 157 trials that are defined as “Not Applicable".

Chu Reims has several departments that took part in Clinical trials: "Hopital Robert Debre; Hematologie Clinique" - 14 trials, "Hopital Robert Debre; DERMATOLOGIE" - 6 trials, "Hôpital Maison Blanche; Service de Neurologie" - 3 trials, "Virologie" - 3 trials